SRS Capital Advisors Inc. Has $411,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

SRS Capital Advisors Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 73.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,978 shares of the company’s stock after purchasing an additional 1,689 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Novo Nordisk A/S were worth $411,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NVO. Westside Investment Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 83.3% during the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after acquiring an additional 649 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $2,408,000. Lazard Asset Management LLC raised its holdings in shares of Novo Nordisk A/S by 182.2% during the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after buying an additional 964,640 shares in the last quarter. CENTRAL TRUST Co lifted its position in shares of Novo Nordisk A/S by 111.6% during the 3rd quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after buying an additional 3,166 shares during the last quarter. Finally, Ieq Capital LLC boosted its stake in Novo Nordisk A/S by 136.6% in the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after buying an additional 15,860 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Price Performance

NVO traded down $0.94 during midday trading on Friday, hitting $123.08. The stock had a trading volume of 5,930,713 shares, compared to its average volume of 4,863,548. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The company has a market cap of $552.33 billion, a P/E ratio of 45.50, a price-to-earnings-growth ratio of 2.16 and a beta of 0.43. The business has a fifty day moving average of $127.21 and a 200 day moving average of $112.77. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.